Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Total Debt (2016 - 2025)

Adma Biologics (ADMA) has disclosed Total Debt for 12 consecutive years, with $72.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Debt changed 0.27% year-over-year to $72.1 million, compared with a TTM value of $72.1 million through Dec 2025, changed 0.27%, and an annual FY2025 reading of $72.1 million, changed 0.27% over the prior year.
  • Total Debt was $72.1 million for Q4 2025 at Adma Biologics, roughly flat from $72.4 million in the prior quarter.
  • Across five years, Total Debt topped out at $144.3 million in Q1 2023 and bottomed at $72.1 million in Q4 2025.
  • Average Total Debt over 5 years is $111.1 million, with a median of $116.0 million recorded in 2023.
  • The sharpest move saw Total Debt skyrocketed 531.83% in 2021, then tumbled 44.61% in 2024.
  • Year by year, Total Debt stood at $94.9 million in 2021, then soared by 50.56% to $142.8 million in 2022, then dropped by 8.57% to $130.6 million in 2023, then crashed by 44.61% to $72.3 million in 2024, then decreased by 0.27% to $72.1 million in 2025.
  • Business Quant data shows Total Debt for ADMA at $72.1 million in Q4 2025, $72.4 million in Q3 2025, and $73.4 million in Q2 2025.